HGH Fragment 176-191

HGH Fragment 176-191 – Benefits & Side Effects

HGH Fragment 176-191 – Protocol

HGH Fragment 176-191 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

HGH Fragment 176-191 – Identification

Common Names: HGH Fragment 176-191, HGH Frag 176-191, hGH(176-191), Somatotropin (176-191), hGH 176-191, CL233, Fragment 176-191

CAS Number: 66004-57-7 (primary); 221231-10-3 (alternate); 68515-73-1 (supplier variants)

Molecular Formula: C₇₈H₁₂₃N₂₃O₂₂S₂ (free peptide); C₇₈H₁₂₅N₂₃O₂₃S (modified variant); may vary with salt forms

Molecular Weight: 1799.08-1817.12 g/mol (varies by formulation); 1859.1 g/mol (reported variant); approximately 1815.08 g/mol (typical)

Origin & Type Classification:

• Source: Synthetic; derived from the C-terminal fragment of naturally occurring human growth hormone sequence

• Biosynthesis: Non-ribosomal; chemically synthesized peptide fragment

• Functional Class: Peptide fragment; lipolytic agent; metabolic regulator; growth hormone fragment

Additional Information:

• Amino Acid Sequence: Tyr-Arg-Lys-Asp-Arg-Phe-Phe-Gly-Phe-Ser-Pro-Phe-Arg-Leu-Ser-Arg (single-letter code: YKDRFFGFSPAFRLS); sequence position 176-191 from full 191-amino acid hGH

• Sequence Length: 16 amino acids (C-terminal fragment of hGH)

• Structural Type: Linear peptide fragment; contains disulfide bonds present in full hGH (cysteine residues at positions 176 and 189 create native disulfide structure from original hGH molecule)

• Salt Form: Available as free peptide, acetate salt, or trifluoroacetic acid (TFA) salt; lyophilized powder common

• Key Structural Features: C-terminal 16-amino acid fragment of hGH; lacks N-terminal region responsible for growth-promoting and somatogenic effects; retains metabolic/lipolytic properties associated with C-terminal region

• Known Synonyms: Somatotropin (176-191), hGH(176-191), HGH frag 176-191, Fragment 176-191, CL233

• Supplier Identification Variations: PubChem CID 16131230 (somatotropin 176-191); DTXSID10216216

• Modified Form Distinction: AOD9604 is a chemically modified version with Tyr→Phe substitution at position 191; HGH Fragment 176-191 is the unmodified sequence from hGH

Database Links:

• PubChem: CID 16131230 (Somatotropin 176-191); CID 16132353 (HGH Fragment 176-191)

• UniProt: Not applicable; HGH Fragment 176-191 is a synthetic peptide fragment not assigned independent UniProt entry; based on P01241 (human GH protein)

• PDB: No dedicated structural entry for HGH Fragment 176-191 as of October 2025

• NCBI: Accessible through PubMed literature database; gene ID 2688 for human GH gene (GH1)

Important Note: The molecular weight and exact formula vary among suppliers depending on salt form (acetate, TFA, or free peptide) and whether modifications are present.

HGH Fragment 176-191 – Research

Study: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Benefits: Helps reduce body fat and weight gain without messing up blood sugar control, unlike full growth hormone.
Link: https://pubmed.ncbi.nlm.nih.gov/11146367/
Summary: Scientists tested a piece of human growth hormone called AOD9604, which is very similar to HGH Fragment 176-191, on fat rats. For 19 days, they gave the rats a small dose by mouth, and the rats gained way less weight—over 50% less than rats that didn't get it. Their fat tissues burned fat better, but it didn't harm their insulin, which helps control sugar in the blood. This means it could be a safe way to fight obesity by targeting fat loss specifically, without the side effects of the whole growth hormone.

Study: Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells
Benefits: Might make cancer drugs work better against breast cancer cells, helping kill them more effectively.
Link: https://pubmed.ncbi.nlm.nih.gov/35783198/
Summary: Researchers used computers to see how HGH Fragment 176-191 sticks to parts of breast cancer cells and helps a chemo drug called doxorubicin bind tighter. In tests on real cancer cells from breasts (MCF-7), mixing the peptide with the drug in tiny particles killed more cancer cells than the drug alone. It made the drug stick better to key spots like hormone receivers, boosting the fight against cancer while possibly lowering doses needed, which cuts side effects for patients. This shows promise for better cancer treatments using this peptide helper.

Study: Detection and in vitro metabolism of AOD9604
Benefits: Stable in the body, breaks down safely, good for fat-burning effects without diabetes risks.
Link: https://pubmed.ncbi.nlm.nih.gov/25208511/
Summary: AOD9604, the modified version of HGH Fragment 176-191, was studied in blood and urine to see how it breaks down. They found it turns into smaller pieces quickly, but one piece stays stable longer. This stability helps it work on fat breakdown like growth hormone does, but without causing high blood sugar problems. It's key for anti-doping checks too, but mainly shows the peptide is safe and effective for mimicking good parts of growth hormone for weight control in lab settings.

Study: Human growth hormone fragments 1-43 and 44-191
Benefits: Affects blood sugar balance in animals, potential for metabolic health without growth side effects.
Link: https://pubmed.ncbi.nlm.nih.gov/8536647/
Summary: This study looked at pieces of human growth hormone, including one like Fragment 176-191 (44-191), in rats and mice. These pieces strongly changed how the body handles sugar, helping keep levels steady, but they didn't make the animals grow bigger like full hormone does. In cell tests, they worked on growth hormone receivers in different animals. It's exciting because it hints at using just the fat and sugar parts for treatments like obesity or diabetes, skipping unwanted growth spurts.

Study: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Benefits: Helps reduce body fat and weight gain without messing up blood sugar control, unlike full growth hormone.
Link: https://pubmed.ncbi.nlm.nih.gov/11146367/
Summary: Scientists tested a piece of human growth hormone called AOD9604, which is very similar to HGH Fragment 176-191, on fat rats. For 19 days, they gave the rats a small dose by mouth, and the rats gained way less weight—over 50% less than rats that didn't get it. Their fat tissues burned fat better, but it didn't harm their insulin, which helps control sugar in the blood. This means it could be a safe way to fight obesity by targeting fat loss specifically, without the side effects of the whole growth hormone.

Study: Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells
Benefits: Might make cancer drugs work better against breast cancer cells, helping kill them more effectively.
Link: https://pubmed.ncbi.nlm.nih.gov/35783198/
Summary: Researchers used computers to see how HGH Fragment 176-191 sticks to parts of breast cancer cells and helps a chemo drug called doxorubicin bind tighter. In tests on real cancer cells from breasts (MCF-7), mixing the peptide with the drug in tiny particles killed more cancer cells than the drug alone. It made the drug stick better to key spots like hormone receivers, boosting the fight against cancer while possibly lowering doses needed, which cuts side effects for patients. This shows promise for better cancer treatments using this peptide helper.

Study: Detection and in vitro metabolism of AOD9604
Benefits: Stable in the body, breaks down safely, good for fat-burning effects without diabetes risks.
Link: https://pubmed.ncbi.nlm.nih.gov/25208511/
Summary: AOD9604, the modified version of HGH Fragment 176-191, was studied in blood and urine to see how it breaks down. They found it turns into smaller pieces quickly, but one piece stays stable longer. This stability helps it work on fat breakdown like growth hormone does, but without causing high blood sugar problems. It's key for anti-doping checks too, but mainly shows the peptide is safe and effective for mimicking good parts of growth hormone for weight control in lab settings.

Study: Human growth hormone fragments 1-43 and 44-191
Benefits: Affects blood sugar balance in animals, potential for metabolic health without growth side effects.
Link: https://pubmed.ncbi.nlm.nih.gov/8536647/
Summary: This study looked at pieces of human growth hormone, including one like Fragment 176-191 (44-191), in rats and mice. These pieces strongly changed how the body handles sugar, helping keep levels steady, but they didn't make the animals grow bigger like full hormone does. In cell tests, they worked on growth hormone receivers in different animals. It's exciting because it hints at using just the fat and sugar parts for treatments like obesity or diabetes, skipping unwanted growth spurts.

HGH Fragment 176-191 – Research Links